Literature DB >> 18259211

Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia.

P Charbel Issa1, H P N Scholl, A Gaudric, P Massin, A E Kreiger, S Schwartz, F G Holz.   

Abstract

PURPOSE: To describe patients with full-thickness macular holes (FTMHs) and lamellar macular holes (LMHs) in association with type 2 idiopathic macular telangiectasia (type 2 IMT).
METHODS: Six patients with either FTMH or LMH and type 2 IMT were evaluated by means of optical coherence tomography (OCT) imaging, funduscopy, and fluorescein angiography.
RESULTS: The age of the examined patients ranged from 57 to 70 years (mean 62.5+/-5.2), and best-corrected visual acuity of the affected eyes ranged from 20/50 to 20/200 (mean 20/100). All eyes showed macular abnormalities typical for nonproliferative type 2 IMT except for one eye with a proliferative disease stage. Three patients had an FTMH, one presenting with bilateral FTMH, and three had an LMH on OCT. In all cases of FTMH, the macular holes did not have elevated margins. Surgery was performed in two patients with a FTHM without subsequent functional improvement.
CONCLUSIONS: The altered foveal anatomy with progressive atrophic changes within the neurosensory retina in type 2 IMT may predispose to the development of FTMH and LMH. Type 2 IMT should be considered in the differential diagnosis in patients presenting with macular holes. The association between the two may reflect alternative pathogenetic mechanisms in the development of macular holes.

Entities:  

Mesh:

Year:  2008        PMID: 18259211     DOI: 10.1038/sj.eye.6703003

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  24 in total

1.  "Doctor, why is my macular hole still open?".

Authors:  Mei Hong Tan; Fred Kuanfu Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-18       Impact factor: 3.117

2.  Spontaneous closure of full-thickness macular hole in type 2 idiopathic macular telangiectasia.

Authors:  Dhananjay Shukla; Ramesh Venkatesh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-22       Impact factor: 3.117

3.  Evolution and management of macular hole secondary to type 2 idiopathic macular telangiectasia.

Authors:  D Shukla
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

4.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2.

Authors:  Michael B Powner; Mark C Gillies; Marina Tretiach; Andrew Scott; Robyn H Guymer; Gregory S Hageman; Marcus Fruttiger
Journal:  Ophthalmology       Date:  2010-08-03       Impact factor: 12.079

5.  [Morphological characteristics in macular telangiectasia type 2].

Authors:  P Charbel Issa; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; F G Holz
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

6.  Metamorphopsia in patients with macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Frank G Holz; Hendrik P N Scholl
Journal:  Doc Ophthalmol       Date:  2009-08-27       Impact factor: 2.379

Review 7.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

8.  Familial asymptomatic macular telangiectasia type 2.

Authors:  Mark C Gillies; Meidong Zhu; Emily Chew; Daniel Barthelmes; Edward Hughes; Haipha Ali; Frank G Holz; Hendrik P N Scholl; Peter Charbel Issa
Journal:  Ophthalmology       Date:  2009-10-07       Impact factor: 12.079

9.  [Functional characteristics of macular telangiectasia type 2].

Authors:  T F C Heeren; E Krüger; F G Holz; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

10.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.